Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus.

Shosaku NomuraAkira ShouzuTakehito TaniuraYoshinori OkudaSeitaro OmotoMasahiko SuzukiTomoki ItoNagaoki Toyoda

Published in: Clinical pharmacology : advances and applications (2023)

The increase in sLOX-1 and IL-6 levels, which indicates the response of scavenger receptors to oxidized low-density lipoproteins in people with T2DM, is mitigated following TOFO and ANA combination therapy. TOFO alone or in combination with ANA may be beneficial for preventing atherosclerosis development in people with T2DM, in addition to its effect on improving HbA1c levels.

Keyphrases

combination therapy
cardiovascular disease
type diabetes
adipose tissue
metabolic syndrome
glycemic control
low density lipoprotein
skeletal muscle
weight loss